Role of IL28B for chronic hepatitis C treatment toward personalized medicine

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 2, 2014, Pages 241-249

  Matsuura, Kentaro ^a,b   Watanabe, Tsunamasa ^a   Tanaka, Yasuhito ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Direct acting antiviral (DAA); Genome wide association study (GWAS); Hepatitis C virus (HCV); Interleukin 28B (IL28B)

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; IFNL4 PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN;

ANTIVIRAL THERAPY; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DNA POLYMORPHISM; DRUG EFFICACY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; HUMAN GENOME PROJECT; INNATE IMMUNITY; LIVER CARCINOGENESIS; LIVER FIBROSIS; MIXED INFECTION; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; VIRAL CLEARANCE; DIRECT-ACTING ANTIVIRAL (DAA); GENETIC POLYMORPHISM; GENETICS; GENOME-WIDE ASSOCIATION STUDY (GWAS); HEPATITIS C VIRUS; HEPATITIS C VIRUS (HCV); INTERLEUKIN 28B (IL28B); TREATMENT OUTCOME; VIROLOGY;

DIRECT-ACTING ANTIVIRAL (DAA); GENOME-WIDE ASSOCIATION STUDY (GWAS); HEPATITIS C VIRUS (HCV); INTERLEUKIN 28B (IL28B);

ANTIVIRAL AGENTS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INDIVIDUALIZED MEDICINE; INTERFERON-ALPHA; INTERLEUKINS; POLYETHYLENE GLYCOLS; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84907284086     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12475     Document Type: Review

References (92)

1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29 (Suppl. 1): 74-81.
2. Yoshida H, Tateishi R, Arakawa Y etal. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53: 425-430.
3. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49: 729-738.
4. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975-982.
5. Hadziyannis SJ, Sette H Jr, Morgan TR etal. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004; 140: 346-355.
6. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 1105-1109.
7. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
8. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009; 41: 1100-1104.
9. Thomas DL, Thio CL, Martin MP etal. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
10. Tanaka Y, Nishida N, Sugiyama M, Tokunaga K, Mizokami M. lambda-Interferons and the single nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. Hepatol. Res. 2010; 40: 449-460.
11. Afdhal NH, McHutchison JG, Zeuzem S etal. Hepatitis C pharmacogenetics: state of the art in. Hepatology 2010; 53: 336-345.
12. Zeuzem S, Andreone P, Pol S etal. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364: 2417-2428.
13. Poordad F, Bronowicki JP, Gordon SC etal. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143: 608-18 e1-5.
14. Jacobson IM, McHutchison JG, Dusheiko G etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 2405-2416.
15. Akuta N, Suzuki F, Sezaki H etal. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48: 372-380.
16. Enomoto N, Sakuma I, Asahina Y etal. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 1996; 334: 77-81.
17. McHutchison JG, Lawitz EJ, Shiffman ML etal. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009; 361: 580-593.
18. McHutchison JG, Manns M, Patel K etal. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069.
19. Conjeevaram HS, Fried MW, Jeffers LJ etal. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-477.
20. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39: 1702-1708.
21. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N. Engl. J. Med. 2004; 350: 2265-2271.
22. Matsuyama N, Mishiro S, Sugimoto M etal. The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol. Res. 2003; 25: 221-225.
23. Tsukada H, Ochi H, Maekawa T etal. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology 2009; 136: 1796-1805.
24. Khakoo SI, Thio CL, Martin MP etal. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305: 872-874.
25. Wang JH, Zheng X, Ke X etal. Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection. Virol. J. 2009; 6: 46.
26. Montes-Cano MA, Caro-Oleas JL, Romero-Gomez M etal. HLA-C and KIR genes in hepatitis C virus infection. Hum. Immunol. 2005; 66: 1106-1109.
27. Rauch A, Kutalik Z, Descombes P etal. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345, 45 e1-7.
28. Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can. J. Gastroenterol. 2007; 21: 447-451.
29. Thomas DL, Astemborski J, Rai RM etal. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-456.
30. Busch MP, Glynn SA, Stramer SL etal. Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors. Transfusion 2006; 46: 469-475.
31. Shiffman ML, Mihas AA, Millwala F etal. Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am. J. Gastroenterol. 2007; 102: 761-766.
32. Thompson AJ, Muir AJ, Sulkowski MS etal. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.
33. Rallon NI, Naggie S, Benito JM etal. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 24: F23-29.
34. Fukuhara T, Taketomi A, Motomura T etal. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-1585, 85 e1-3.
35. Charlton MR, Thompson A, Veldt BJ etal. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-324.
36. Mangia A, Thompson AJ, Santoro R etal. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827, 7 e1.
37. Sakamoto N, Nakagawa M, Tanaka Y etal. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J. Med. Virol. 2011; 83: 871-878.
38. Yu ML, Huang CF, Huang JF etal. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011; 53: 7-13.
39. Moghaddam A, Melum E, Reinton N etal. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53: 746-754.
40. Asselah T, De Muynck S, Broet P etal. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J. Hepatol. 2012; 56: 527-532.
41. Antaki N, Bibert S, Kebbewar K etal. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. J. Viral Hepat. 2012; 20: 59-64.
42. Abdo AA, Al-Ahdal MN, Khalid SS etal. IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection. Hepatol. Int. 2013; 7: 533-538.
43. Antaki N, Bibert S, Kebbewar K etal. IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5. Gut 2012; 61: 1640-1641.
44. Seto WK, Tsang OT, Liu K etal. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. J. Viral Hepat. 2013; 20: 470-477.
45. Ragheb M, Nemr N, Kishk R. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4. Liver Int. 2013 Sep 16; doi: 10.1111/liv.12321 [Epub ahead of print].
46. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N. Engl. J. Med. 1999; 340: 1228-1233.
47. Conry-Cantilena C, VanRaden M, Gibble J etal. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N. Engl. J. Med. 1996; 334: 1691-1696.
48. Duggal P, Thio CL, Wojcik GL etal. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann. Intern. Med. 2013; 158: 235-245.
49. Grebely J, Petoumenos K, Hellard M etal. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010; 52: 1216-1224.
50. Tillmann HL, Thompson AJ, Patel K etal. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-1592, 92 e1.
51. Grebely J, Page K, Sacks-Davis R etal. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C Virus infection. Hepatology 2014; 59: 109-120.
52. Grebely J, Matthews GV, Dore GJ. Treatment of acute HCV infection. Nat. Rev. Gastroenterol. Hepatol. 2011; 8: 265-274.
53. Mangia A, Santoro R, Copetti M etal. Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. J. Hepatol. 2013; 59: 221-228.
54. Fabris C, Falleti E, Cussigh A etal. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J. Hepatol. 2011; 54: 716-722.
55. Abe H, Ochi H, Maekawa T etal. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J. Hepatol. 2010; 53: 439-443.
56. Noureddin M, Wright EC, Alter H etal. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology 2013; 58: 1548-1557.
57. Barreiro P, Pineda JA, Rallon N etal. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J. Infect. Dis. 2011; 203: 1629-1636.
58. Bochud PY, Bibert S, Kutalik Z etal. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012; 55: 384-394.
59. Marabita F, Aghemo A, De Nicola S etal. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011; 54: 1127-1134.
60. Akuta N, Suzuki F, Seko Y etal. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology 2012; 56: 2134-2141.
61. Miura M, Maekawa S, Kadokura M etal. Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C. Hepatol. Int. 2012; 6: 386-396.
62. Joshita S, Umemura T, Katsuyama Y etal. Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection. Hum. Immunol. 2012; 73: 298-300.
63. Asahina Y, Tsuchiya K, Nishimura T etal. Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C. J. Gastroenterol. 2013 Jul 17: doi: 10.1007/S00535-013-0858-2 [Epub ahead of print].
64. Poordad F, McCone J Jr, Bacon BR etal. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1195-1206.
65. Bacon BR, Gordon SC, Lawitz E etal. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1207-1217.
66. Jacobson IM, Catlett I, Marcellin P etal. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. J. Hepatol. 2011; 54 (Suppl. 1): S542.
67. Pol S, Aerssens J, Zeuzem S etal. Similar SVR rates in IL28B CC, CT or TT prior relapser, partial or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study. J. Hepatol. 2011; 54 (Suppl. 1): S6.
68. Akuta N, Suzuki F, Hirakawa M etal. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52: 421-429.
69. Fried MW, Buti M, Dore GJ etal. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-Naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-1929.
70. Sulkowski MS, Asselah T, Lalezari J etal. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology 2013; 57: 2143-2154.
71. McHutchison JG, Manns MP, Muir AJ etal. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 2010; 362: 1292-1303.
72. Bota S, Sporea I, Sirli R, Neghina AM, Popescu A, Strain M. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis. Clin. Drug Investig. 2013; 33: 325-331.
73. Lawitz E, Rodriguez-Torres M, Stoehr A etal. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. J. Hepatol. 2013; 59: 11-17.
74. Lok AS, Gardiner DF, Lawitz E etal. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 2012; 366: 216-224.
75. Chayama K, Takahashi S, Toyota J etal. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55: 742-748.
76. Chu TW, Kulkarni R, Gane EJ etal. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 2012; 142: 790-795.
77. Zeuzem S, Soriano V, Asselah T etal. Faldaprevir and deleobuvir for HCV genotype 1 infection. N. Engl. J. Med. 2013; 369: 630-639.
78. Kotenko SV, Gallagher G, Baurin VV etal. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003; 4: 69-77.
79. Sheppard P, Kindsvogel W, Xu W etal. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003; 4: 63-68.
80. Sarasin-Filipowicz M, Oakeley EJ, Duong FH etal. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl Acad. Sci. U. S. A. 2008; 105: 7034-7039.
81. Feld JJ, Nanda S, Huang Y etal. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007; 46: 1548-1563.
82. Honda M, Sakai A, Yamashita T etal. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.
83. Urban TJ, Thompson AJ, Bradrick SS etal. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-1896.
84. Asahina Y, Izumi N, Hirayama I etal. Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. Gastroenterology 2008; 134: 1396-1405.
85. Asahina Y, Tsuchiya K, Muraoka M etal. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology 2012; 55: 20-29.
86. Abe H, Hayes CN, Ochi H etal. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J. Hepatol. 2011; 54: 1094-1101.
87. Thomas E, Gonzalez VD, Li Q etal. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012; 142: 978-988.
88. Watanabe T, Sugauchi F, Tanaka Y etal. Hepatitis C virus kinetics by administration of pegylated interferon-alpha in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene. Gut 2013; 62: 1340-1346.
89. Zhang S, Kodys K, Li K, Szabo G. Human type 2 myeloid dendritic cells produce interferon-lambda and amplify interferon-alpha in response to hepatitis C virus infection. Gastroenterology 2013; 144: 414-425 e7.
90. Yoshio S, Kanto T, Kuroda S etal. Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-lambda in response to hepatitis C virus. Hepatology 2013; 57: 1705-1715.
91. Prokunina-Olsson L, Muchmore B, Tang W etal. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 2013; 45: 164-171.
92. Bibert S, Roger T, Calandra T etal. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J. Exp. Med. 2013; 210: 1109-1116.